A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused by a ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

Yet at the annual meeting of the Menopause Society earlier this fall, researchers presented new evidence that hormone therapy ...

Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

PTC Therapeutics inks global license and collaboration agreement with Novartis for PTC518 Huntington's disease programme: Warren, New Jersey Tuesday, December 3, 2024, 14:00 Hrs [ ...

Basel: Novartis has announced that it has entered into a global license and collaboration agreement with PTC Therapeutics for ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG ...

PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the ...